Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$489.2MCash, Jun 2026
+6%Share Count, 1 Year
Follow TVTX by emailGet an email when TVTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TVTX, unsubscribe in one click. Privacy
📣 What TVTX Says Is Next
2H 2027 · “The Company is continuing to enroll new patients in the pivotal Phase 3 HARMONY Study, with topline data anticipated in 2H 2027.”
Company press release, Aug 4, 2026 · SEC filing
in 2027 · “The SPARX Study evaluating FILSPARI in post-transplant patients with recurrent IgAN or FSGS has completed enrollment, with data presentations anticipated in 2027.”
Company press release, Aug 4, 2026 · SEC filing
2H 2027 · “In April 2026, the Company dosed the first new patient following the study restart, with topline data anticipated in 2H 2027.”
Company press release, May 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
TVTX reported $489.2M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.